Development of Subtle Iron Deficiency During Vitamin E Treatment For Metabolic Dysfunction-Associated Steatotic Liver Disease.

IF 2.3 Q3 NUTRITION & DIETETICS
Journal of Dietary Supplements Pub Date : 2025-01-01 Epub Date: 2025-02-17 DOI:10.1080/19390211.2025.2465414
Maren C Podszun, Ahmad Samer Alawad, Shilpa Lingala, Nevitt Morris, Wen Chun A Huang, Yaron Rotman
{"title":"Development of Subtle Iron Deficiency During Vitamin E Treatment For Metabolic Dysfunction-Associated Steatotic Liver Disease.","authors":"Maren C Podszun, Ahmad Samer Alawad, Shilpa Lingala, Nevitt Morris, Wen Chun A Huang, Yaron Rotman","doi":"10.1080/19390211.2025.2465414","DOIUrl":null,"url":null,"abstract":"<p><p>Vitamin E is an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) but associated with hemorrhagic complications when used for other indications. We aimed to determine the risk of developing iron deficiency during treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) with vitamin E. Iron status was monitored prospectively in 20 people with MASLD treated with 200 - 800 IU/d vitamin E (https://clinicaltrials.gov/study/NCT01792115). To gain mechanistic insights liver histology, hepatic gene expression, hepatic 4-hydroxynonenal, haptoglobin genotype and plasma vitamin E levels were assessed. We found iron deficiency to occur in 11/20 subjects (55%) after a median 11 weeks (range 4-13) of vitamin E treatment, and anemia to occur in 6 of the 11 (30% of study population) after 23 weeks (16-36). Ferritin (84.5 ± 85.2 to 47.8 ± 54.9μg/L, <i>p</i> < 0.001) and mean corpuscular volume (MCV, 86.2 ± 4.9 to 84.3±4.3fL, <i>p</i> = 0.003) significantly decreased, with a concomitant rise in red-cell distribution width (RDW, 13.4 ± 1.3 to 14.4 ± 1.9%, <i>p</i> = 0.003). A gastrointestinal bleeding source was found in 75% of subjects with complete work-up. Iron deficiency occurred in all diabetics vs. 47% of non-diabetics (<i>p</i> 0.007). Iron deficiency risk was not associated with cirrhosis, platelet count, prothrombin time, haptoglobin genotype, or plasma vitamin E level. Changes in hepatic gene expression and oxidative stress were suggestive of an extrahepatic effect. Iron deficiency resolved with appropriate care even with continued vitamin E treatment. We conclude that occult gastrointestinal bleeding and iron deficiency were frequently observed during vitamin E treatment, possibly reflecting an effect on platelet function. Close monitoring is warranted during the first months of treatment, especially in diabetics and subjects with risk factors for gastrointestinal bleeding.</p>","PeriodicalId":15646,"journal":{"name":"Journal of Dietary Supplements","volume":" ","pages":"284-299"},"PeriodicalIF":2.3000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11851352/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dietary Supplements","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/19390211.2025.2465414","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0

Abstract

Vitamin E is an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) but associated with hemorrhagic complications when used for other indications. We aimed to determine the risk of developing iron deficiency during treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) with vitamin E. Iron status was monitored prospectively in 20 people with MASLD treated with 200 - 800 IU/d vitamin E (https://clinicaltrials.gov/study/NCT01792115). To gain mechanistic insights liver histology, hepatic gene expression, hepatic 4-hydroxynonenal, haptoglobin genotype and plasma vitamin E levels were assessed. We found iron deficiency to occur in 11/20 subjects (55%) after a median 11 weeks (range 4-13) of vitamin E treatment, and anemia to occur in 6 of the 11 (30% of study population) after 23 weeks (16-36). Ferritin (84.5 ± 85.2 to 47.8 ± 54.9μg/L, p < 0.001) and mean corpuscular volume (MCV, 86.2 ± 4.9 to 84.3±4.3fL, p = 0.003) significantly decreased, with a concomitant rise in red-cell distribution width (RDW, 13.4 ± 1.3 to 14.4 ± 1.9%, p = 0.003). A gastrointestinal bleeding source was found in 75% of subjects with complete work-up. Iron deficiency occurred in all diabetics vs. 47% of non-diabetics (p 0.007). Iron deficiency risk was not associated with cirrhosis, platelet count, prothrombin time, haptoglobin genotype, or plasma vitamin E level. Changes in hepatic gene expression and oxidative stress were suggestive of an extrahepatic effect. Iron deficiency resolved with appropriate care even with continued vitamin E treatment. We conclude that occult gastrointestinal bleeding and iron deficiency were frequently observed during vitamin E treatment, possibly reflecting an effect on platelet function. Close monitoring is warranted during the first months of treatment, especially in diabetics and subjects with risk factors for gastrointestinal bleeding.

维生素E治疗代谢功能障碍相关脂肪变性肝病期间微量缺铁的发展
维生素E是代谢功能障碍相关脂肪性肝炎(MASH)的有效治疗方法,但当用于其他适应症时,与出血性并发症有关。我们的目的是确定在用维生素E治疗代谢功能障碍相关脂肪变性肝病(MASLD)期间发生缺铁的风险。我们对20名MASLD患者进行了前瞻性的铁状态监测,这些患者接受200 - 800 IU/d维生素E治疗(https://clinicaltrials.gov/study/NCT01792115)。为了获得机制的见解,肝组织,肝基因表达,肝4-羟基烯醛,触珠蛋白基因型和血浆维生素E水平进行了评估。我们发现,在维生素E治疗中位数11周(范围4-13周)后,有11/20(55%)的受试者出现缺铁,而在23周(16-36周)后,11人中有6人(30%)出现贫血。铁蛋白(84.5±85.2 ~ 47.8±54.9μg/L, p < 0.001)和平均红细胞体积(MCV, 86.2±4.9 ~ 84.3±4.3fL, p = 0.003)显著降低,红细胞分布宽度(RDW, 13.4±1.3 ~ 14.4±1.9%,p = 0.003)显著升高。在75%的受试者中发现了胃肠道出血源。所有糖尿病患者缺铁,而非糖尿病患者缺铁的比例为47% (p 0.007)。缺铁风险与肝硬化、血小板计数、凝血酶原时间、触珠蛋白基因型或血浆维生素E水平无关。肝脏基因表达和氧化应激的变化提示肝外作用。铁缺乏症通过适当的护理甚至持续的维生素E治疗得以解决。我们得出结论,在维生素E治疗期间经常观察到隐性胃肠道出血和铁缺乏,可能反映了血小板功能的影响。在治疗的头几个月密切监测是必要的,特别是糖尿病患者和有胃肠道出血危险因素的受试者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Dietary Supplements
Journal of Dietary Supplements Agricultural and Biological Sciences-Food Science
CiteScore
6.10
自引率
0.00%
发文量
34
期刊介绍: The Journal of Dietary Supplements (formerly the Journal of Nutraceuticals, Functional & Medical Foods) has been retitled to reflect the bold departure from a traditional scientific journal presentation to a leading voice for anyone with a stake in dietary supplements. The journal addresses important issues that meet the broad range of interests from researchers, regulators, marketers, educators, and health professionals from academic, governmental, industry, healthcare, public health, and consumer education sectors. This vital tool not only presents scientific information but interprets it - helping you more readily pass it on to your students, patients, clients, or company.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信